A61P 9 - Drugs for disorders of the cardiovascular system

Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
12/2006
12/06/2006	CN1287809C Method of extracting total flavone product from halenalin plant full flower
12/06/2006	CN1287808C Ginkgo leaf extract composition
12/06/2006	CN1287803C Partial mouth composition for promoting whole body health and its application
12/06/2006	CN1287791C Combination of semisolid framework preparation of nimodipine
12/06/2006	CN1287785C Use of pepper amide compound in preparation of drug or healthcare product for reducing blood fat
12/06/2006	CN1287784C Troxerution guttate pill and preparation method thereof
12/06/2006	CN1287783C Application of probuco monoester in treating angiocardiopathy and inflammatory disease
12/05/2006	USRE39419 Estrogen agonist/antagonist metabolites
12/05/2006	US7145037 Adamantane derivatives with neuroprotective, antidepressant and anti-ischaemic activities, and process for preparing them
12/05/2006	US7145036 Highly pure (R,R)-formoterol L-tartrate composition obtained by crystallizing a first polymorph of (R,R)-formoterol L-tartrate from aqueous isopropyl alcohol
12/05/2006	US7145025 Structural carotenoid analogs for the inhibition and amelioration of disease
12/05/2006	US7145009 Pirazino(aza)indole derivatives
12/05/2006	US7144916 Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
12/05/2006	US7144914 3,7-diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias
12/05/2006	US7144909 Phenoxy substituted benzocondensed heteroaryl derivatives as thyroid receptor ligands
12/05/2006	US7144908 Prophylaxis, therapy of respiratory system disorders
12/05/2006	US7144906 Heterocyclic compounds
12/05/2006	US7144902 Prodrugs of thrombin inhibitors
12/05/2006	US7144899 Thrombin inhibitors
12/05/2006	US7144892 Treatment of cardiovascular and related pathologies
12/05/2006	US7144882 Central nervous system disorders; psychological disorders; inflammatory bowel disorders
12/05/2006	US7144879 Substituted metal-phthalocyanines, their preparation and the use thereof
12/05/2006	US7144873 Therapy for anticancer agents, blood disorders; dissolving in nonaqueous solvent
12/05/2006	US7144872 1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-carboxamides; adenosine receptors (A2A); for stimulating mammalian coronary vasodilatation for therapy and imaging the heart
12/05/2006	US7144871 Partial and full agonists of A1 adenosine receptors
12/05/2006	US7144863 Powders of glucagon-like peptide is complexed with a polypeptide of polylysine, polyarginine, polyornithine, protamine, putrescine, spermine, spermidine, and histone; treating diabetes, hyperglycemia, obesity, irritable bowel syndrome, myocardial infarction; drug delivery by inhalation
12/05/2006	US7144860 Amd to ischemic tissue; treating atherosclerosis and restenosis.
12/05/2006	US7144707 Determination of risk and treatment of complications of prematurity
12/05/2006	US7144586 Compositions for preventing hormone induced adverse effects
12/05/2006	CA2396458C Pyrimidine carboxamides useful as inhibitors of pde4 isozymes
12/05/2006	CA2387531C Purine derivatives
12/05/2006	CA2384929C A novel angiogenesis inhibitor
12/05/2006	CA2307121C Dofetilide polymorphs
11/2006
11/30/2006	WO2006127907A2 Localized delivery of cardiac inotropic agents
11/30/2006	WO2006127007A2 Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
11/30/2006	WO2006126712A1 Smooth muscle contraction inhibitor
11/30/2006	WO2006126688A1 Agent for improvement of insulin resistance
11/30/2006	WO2006126654A1 Novel compound colletoic acid
11/30/2006	WO2006126600A1 Pharmaceutical composition for vascular occlusive disease
11/30/2006	WO2006126514A1 Arylacetate derivative having isoxazole skeleton
11/30/2006	WO2006126295A1 Preventive and/or therapeutic agent for diabetic vascular disorder and respiratory disorder
11/30/2006	WO2006126082A2 Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
11/30/2006	WO2006126081A2 Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors
11/30/2006	WO2006125847A1 Production of and antihypertensive properties of peptides derived from egg white proteins
11/30/2006	WO2006125805A1 Thiazole derivatives and use thereof
11/30/2006	WO2006125621A1 Substituted piperidines as renin inhibitors
11/30/2006	WO2006125554A1 Use of cyanopyrimidines for the treatment of cardiovascular diseases
11/30/2006	WO2006125548A1 Use of pyrazolopyrimidine against cardiovascular diseases
11/30/2006	WO2006125322A1 Modulation of the integrin-linked kinase signaling pathway provides beneficial human cardiac hypertrophy and post myocardial infarction remodeling
11/30/2006	WO2006125321A1 Modulation of the integrin linked kinase signaling pathway to promote cardiac cell proliferation and self-renewal
11/30/2006	WO2006125304A1 Pharmaceutical compositions for treating or preventing coronary artery disease
11/30/2006	WO2006113261A3 Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
11/30/2006	WO2006107902A3 Use of spirostenols to treat mitochondrial disorders
11/30/2006	WO2006047799A3 Treatment of heart failure with csf-1
11/30/2006	WO2005080384A9 Benzimidazole derivative and use as aii receptor antagonist
11/30/2006	US20060270839 Crystallization of IGF-1
11/30/2006	US20060270832 Novel x-conotoxin peptides (-II)
11/30/2006	US20060270719 2-[(Cyclopropylmethoxy-benzenesulfonyl)-(4-[1,2,3]triazol-2-yl-benzyl)-amino]-N-hydroxy-acetamide; selective inhibitors of matrix-degrading metalloproteinases, especially MT1-MMP, MMP-2 and MMP-9; Osteoporosis; Antitumor, antiproliferative agents
11/30/2006	US20060270718 e.g. N-(4-{1-Hydroxy-1-[1-(2-methoxyethyl)-1H-pyrrol-2-yl]-ethyl}-phenyl)-N-methyl-benzenesulfonamide; liver X receptor (LXR) agonist; antidiabetic, antiproliferative agent; lipid, metabolic disorders, obesity, diabetes, hypercholesterolemia, atherosclerosis, hyperlipoproteinemia
11/30/2006	US20060270717 Therapeutic combination
11/30/2006	US20060270706 Cyclic amine derivative having heteroaryl ring
11/30/2006	US20060270699 Stabilization of hypoxia inducible factor (HIF) alpha
11/30/2006	US20060270697 Treatment method
11/30/2006	US20060270681 Pyridazine derivatives
11/30/2006	US20060270679 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
11/30/2006	US20060270676 Hydrazono-malonitriles
11/30/2006	US20060270665 Combination comprising an agent decreasing VEGF activity and an agent decreasing EGF activity
11/30/2006	US20060270660 Processes for preparing substituted pyrimidines
11/30/2006	US20060270649 Azetidine derivatives, their preparation and medicaments containing them
11/30/2006	US20060270615 Compositions suitable for the treatment of damage caused by ischemia/reper-fusion or oxidative stress
11/30/2006	US20060270599 Inhibiting angiogenesis using molecules that enhance plasmin formation or prolong plasmin activity
11/30/2006	US20060270009 Oxidation resistance; from hesperidin using Aspergillus fermentation
11/30/2006	US20060269996 Human voltage gated sodium channel beta1A subunit and methods of use
11/30/2006	US20060269959 Sequences of an Ih ion channel and use thereof
11/30/2006	DE102005024494A1 Verwendung von Cyanopyrimidinen Use of Cyanopyrimidinen
11/30/2006	DE102005024493A1 Verwendung von Pyrazolopyrimidinen Use of pyrazolopyrimidines
11/30/2006	CA2610521A1 Modulation of the integrin-linked kinase signaling pathway provides beneficial human cardiac hypertrophy and post myocardial infarction remodeling
11/30/2006	CA2609937A1 Modulation of the integrin linked kinase signaling pathway to promote cardiac cell proliferation and self-renewal
11/30/2006	CA2609595A1 Preventive and/or therapeutic agents for diabetic vascular disorders and respiratory disorders
11/30/2006	CA2609456A1 Localized delivery of cardiac inotropic agents
11/30/2006	CA2608685A1 Substituted piperidines as renin inhibitors
11/30/2006	CA2608672A1 Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
11/30/2006	CA2607385A1 Thiazole derivatives and their use for the treatment and/or prophylaxis of disorders and diseases
11/30/2006	CA2606902A1 Insulin resistance improver
11/29/2006	EP1726647A1 Gene promoting vascular endothelial cell growth
11/29/2006	EP1726590A1 Cycloalkanopyridine derivative
11/29/2006	EP1726585A1 Diaryl-substituted five-membered heterocycle derivative
11/29/2006	EP1726584A1 2-aminoquinazoline derivative
11/29/2006	EP1726582A2 Compounds and methods for the inhibition of the expression of vcam-1
11/29/2006	EP1726318A1 Medicine/gene leaching type stent
11/29/2006	EP1726313A1 Drug for preventing and treating arteriosclerosis
11/29/2006	EP1726306A1 Fasudil-containing preparation and method of improving stability thereof
11/29/2006	EP1725550A2 Pyrrole-derivatives as factor xa inhibitors
11/29/2006	EP1725546A1 Pyrazolyl indolyl derivatives as ppar activators
11/29/2006	EP1725538A1 Pyridazinone ureas as antagonists of a4 integrins
11/29/2006	EP1725530A1 Organic compounds
11/29/2006	EP1725523A1 Ion channel modulators
11/29/2006	EP1725121A1 Novel dietary supplements or foodstuff based on unsaturated fatty acids and uses thereof
11/29/2006	EP1503987B1 Preparation of an anhydrous quinoline-based cetp inhibitor by crystallization
11/29/2006	EP1313504B1 Methods and compositions for inhibiting angiogenesis

1 ... 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 ... 1595